To evaluate the relationship of selected medical conditions and medications with cancers of the renal pelvis and ureter, we interviewed 308 subjects with renal pelvis cancer, 194 subjects with ureter cancer and 496 control subjects in 3 areas of the United States. After controlling for the effects of smoking, age, gender and geographic residence, a history of hypertension (reported to have been diagnosed more than 5 years before interview) was associated with a small but significantly increased risk (odds ratio [OR] 5 1.3; 95% confidence interval [CI], 1.0-1.8), whereas no relationship was observed with a variety of other medical conditions or medications. Stratified analysis showed that the risk associated with hypertension was twice as high among users of diuretics or other antihypertensive drugs (OR 5 2.4; 95% CI, 1.1-4.9) as it was among those who never used these medications (OR 5 1.2; 95% CI, 0.8-1.7). Our findings suggest that the association previously reported between hypertension and renal cell cancer may extend to cancers of the renal pelvis and ureter. Int. J. Cancer, 70: 265-268, 1997.r 1997 Wiley-Liss, Inc.* Cancers of the renal pelvis and ureter, both lined by transitional epithelium, are uncommon tumors that account for less than 1% of all newly diagnosed cancers in the United States (Devesa et al., 1990). However, the incidence rates have been rising by 2 to 4% annually among both men and women (Devesa et al., 1990). Although there have been relatively few epidemiologic studies, the major risk factor is cigarette smoking, which is believed to account for most of these tumors .Previous studies have linked heavy use of analgesics, especially preparations containing phenacetin, to an elevated risk of renal pelvis and ureter cancers (McCredie et al., 1982(McCredie et al., , 1993McLaughlin et al., 1983;Jensen et al., 1989). However, data from the present study revealed no association (Linet et al., 1995), probably because phenacetin was discontinued many years ago in the United States and the carcinogenic effects may no longer be apparent. To investigate further the role of prior medical conditions and pharmaceutical agents in the development of these cancers, we examined data from a large-scale, population-based, case-control study conducted in 3 geographic areas in the United States.
METHODSDetailed methods for this study have already been described Linet et al., 1995). Briefly, cases were individuals aged 20-79, newly diagnosed with microscopically confirmed cancers of the renal pelvis or ureter between January 1, 1983, and December 31, 1986, and living in New Jersey, Iowa or Los Angeles County, California. Non-white cases in these areas were excluded from the study because of very small numbers. Population-based control subjects were frequency-matched to the index cases based on age (5-year group), sex, and geographic area and were chosen by random digit dialing (RDD) (Waksberg, 1978) for cases younger than 65 or selected from Medicare files of the Health Care Financing Administration (HCFA) for ...